Q32 Bio/$QTTB
1D1W1MYTD1Y5YMAX
Capital at risk
About Q32 Bio
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
- Ticker
- $QTTB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 22
- Headquarters
- Waltham, United States
- Website
- www.q32bio.com
Q32 Bio Metrics
BasicAdvanced
$245M
3.62
$2.27
-0.38
-
Price and volume
Market cap
$245M
Beta
-0.38
52-week high
$23.57
52-week low
$1.91
Average daily volume
922K
Financial strength
Current ratio
20.301
Quick ratio
19.676
Long term debt to equity
0.043
Total debt to equity
0.05
Interest coverage (TTM)
23.85%
Profitability
EBITDA (TTM)
21.818
Gross margin (TTM)
73.30%
Net profit margin (TTM)
62.87%
Operating margin (TTM)
39.94%
Revenue per employee (TTM)
$2,440,000
Management effectiveness
Return on assets (TTM)
14.74%
Return on equity (TTM)
72.14%
Valuation
Price to earnings (TTM)
3.619
Price to revenue (TTM)
2.272
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-6.157
Free cash flow yield (TTM)
-16.24%
Free cash flow per share (TTM)
-1.337
Growth
Earnings per share change (TTM)
-152.95%
What the Analysts think about Q32 Bio
Analyst ratings (Buy, Hold, Sell) for Q32 Bio stock.
Analyst projections of the future price of Q32 Bio stock.
Q32 Bio Financial Performance
Revenues and expenses
Q32 Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Q32 Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.